Table 3.
Predictive performance of models for ACLF development in patients with HBV-related decompensated cirrhosis in the derivation cohort and validation cohorts.
| Derivation cohort (n = 970) |
Validation cohort (n = 458) |
|||
|---|---|---|---|---|
| C-index (95% CI) | p value | C-index (95% CI) | p value | |
| Model | 0.902 (0.874-0.930) | 0.862 (0.805-0.920) | ||
| iMELD | 0.840 (0.807-0.873) | <0.001 | 0.821 (0.767-0.876) | 0.033 |
| MELD-sodium | 0.859 (0.828-0.891) | <0.001 | 0.823 (0.764-0.882) | 0.027 |
| Child-Pugh | 0.769 (0.727-0.810) | <0.001 | 0.762 (0.594-0.750) | <0.001 |
| CLIF-C AD | 0.783 (0.737-0.829) | <0.001 | 0.771 (0.707-0.835) | <0.001 |
ACLF, acute-on-chronic liver failure; AD, acute decompensation; CLIF-C AD, CLIF consortium acute decompensation score; iMELD, integrated MELD; MELD, model for end-stage liver disease.